A synthetic peptide-based erythropoiesis stimulating agent (ESA) (Hematide) demonstrates dose dependent activity and is well tolerated in a phase I single dose, dose escalating study in normal healthy volunteers (NHV).

被引：0
|
作者：
Stead, RB
Lambert, J
Wessels, D
Iwashita, J
Leuther, K
Woodburn, K
Schatz, P
Duliege, AM
机构：
[1] BioPharma Consulting Serv LLC, Bellevue, WA USA
[2] Parexel, London, England
[3] Affymax Inc, Palo Alto, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：773S / 773S
页数：1
相关论文
共 11 条
  • [1] Pharmacokinetics (PK), safety, and pharmacodynamics (PD) of Hematide™ a synthetic peptide-based erythropoiesis stimulating agent (ESA), in a phase 1 single dose, dose escalating study in normal healthy volunteers (NHVS).
    Lambert, JR
    Duliege, AM
    Stead, R
    Wessels, DH
    Pcikup, EN
    Iwashita, J
    Leuther, K
    Woodburn, K
    Schatz, P
    Naso, R
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P19 - P19
  • [2] Hematide™, a synthetic peptide-based erythropoiesis stimulating agent (ESA), demonstrates erythropoietic activity in a phase 2 single dose, dose escalating study in patients with Chronic Kidney Disease (CKD)
    Duliege, AM
    Macdougall, L
    Duncan, N
    Wessels, D
    Iwashita, J
    Schatz, P
    Naso, R
    Stead, R
    Lambert, J
    [J]. BLOOD, 2005, 106 (11) : 986A - 986A
  • [3] Hematide™, a synthetic peptide-based erythropoiesis stimulating agent (ESA), demonstrates erythropoietic activity in single dose studies in normal healthy volunteers (HV) and in patients with chronic kidney disease (CKD)
    Duliege, A. M.
    Macdougall, I. C.
    Goldsmith, D.
    Wessels, D.
    Iwashita, J.
    Schatz, P.
    Naso, R.
    Stead, R.
    Lambert, J.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 155 - 155
  • [4] NE-180, a novel glycoPEGylated erythropoietin demonstrates dose-dependent activity in a phase 1 single dose, dose escalating study in normal human volunteers (NHV).
    Wallin, Bruce A.
    Ramjit, Denise
    Seiberling, Michael
    Zopf, David
    [J]. BLOOD, 2006, 108 (11) : 340A - 340A
  • [5] Long-term safety, tolerability, and pharmacodynamics of Hematide™ a synthetic peptide-based erythropoiesis stimulating agent in a phase II, multi-dose study in patients with chronic kidney disease
    Wiecek, Andrzej
    Macdougall, Iain C.
    Mikhail, Ashraf
    Tucker, Beatriz
    Yaqoob, Magdi
    Nowicki, Michal
    Mysliwiec, Michal
    Leong, Robert
    Iwashita, Julie
    Duliege, Anne-Marie
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 155 - 155
  • [6] CERA (Continuous erythropoiesis receptor activator) demonstrates dose-dependent activity and is well tolerated in phase 1 multiple ascending dose studies.
    Dougherty, FC
    Reigner, B
    Jordan, P
    Pannier, A
    [J]. BLOOD, 2003, 102 (11) : 204A - 204A
  • [7] GlycoPEGylated filgrastim XM22 demonstrates dose-dependent activity in comparison to pegfilgrastim in a dose-escalating study in healthy volunteers after body-weight dependent single dose
    Lubenau, Heinz
    Pokorny, Rolf
    Lopez-Lazaro, Luis
    Bias, Peter
    Wallin, Bruce
    Hinderer, Walter
    Maly, Anne-Katrin
    Seiberling, Michael
    [J]. BLOOD, 2007, 110 (11) : 89B - 89B
  • [8] EVALUATION OF PHARMACOKINETICS AND SAFETY OF THE IGM ENRICHED IMMUNOGLOBULIN CONCENTRATE BT086 IN HEALTHY VOLUNTEERS - RESULTS OF A DOSE-ESCALATING SINGLE DOSE PHASE I STUDY
    Schmiedl, S.
    Szymanski, J.
    Wartenberg-Demand, A.
    Remy, A.
    Thuermann, P.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 : 21 - 21
  • [9] Ensovibep, a SARS-CoV-2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first-in-human, ascending single-dose Phase 1 study
    Stojcheva, Nina
    Gladman, Stacy
    Soergel, Marianne
    Zitt, Christof
    Drake, Roxana
    Lockett, Tony
    Marchand, Carine
    Fustier, Pierre
    Stavropoulou, Vaia
    Fernandez, Elena
    Pettigiani, Nathana Lopes
    Watkins, Kate
    Puri, Adeep
    Watson, Randall
    Legenne, Philippe
    Stumpp, Michael T.
    Boyce, Malcolm
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (07) : 2295 - 2303
  • [10] Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study
    Cohen, Dani
    Atsmon, Jacob
    Artaud, Cecile
    Meron-Sudai, Shiri
    Gougeon, Marie-Lise
    Bialik, Anya
    Goren, Sophy
    Asato, Valeria
    Ariel-Cohen, Ortal
    Reizis, Arava
    Dorman, Alexandra
    Hoitink, Carla W. G.
    Westdijk, Janny
    Ashkenazi, Shai
    Sansonetti, Philippe
    Mulard, Laurence A.
    Phalipon, Armelle
    [J]. LANCET INFECTIOUS DISEASES, 2021, 21 (04): : 546 - 558
12